|  |  |  |
| --- | --- | --- |
| **First Name** | **Last Name** | **Company: Relationship [X Relationship Ended];** |
| Erik K.  | Alexander | Veracyte Inc. (Afirma): Consultant; Roche Diagnostics: Researcher (X Relationship Ended) |
| Trevor E. | Angell | Immunovant,Inc.: Research funding to institution |
| Andrew J. | Bauer | Egetis/Rare Thyroid Therapeutics: Consultant; IBSA Pharm: Consultant; Bayer: Speaker (X Relationship Ended) |
| Sofie | Bliddal | Merck: Speaker's fee (X Relationship Ended) |
| Erik | Blomain | HMP Global: CME Speaker Honorarium (X Relationship Ended) |
| Kristien | Boelaert | Lilly: Advisory Board for use of Selpercatinib |
| Eveline | Bruinstroop | Madrigal: Advisor, Speaker; Aligos: Consultant |
| Naifa | Busaidy | Exelixis: Consulting; Eisai: Ad board (X Relationship Ended); Novartis: Research funding (X Relationship Ended) |
| Maria E.  | Cabanillas | Exexllxis:Advisory Board (X Relationship Ended); Bayer: Advisory Board (X Relationship Ended); Bayer: Consulting (X Relationship Ended); Genetech: Research Funding; Merick: Research Funding |
| Daniele  | Cappellani | Merck: Consultant; S.P.A Societa Prodotti Antibiotici: Speaker (X Relationship Ended) |
| Anne  | Cappola | Xyone Therapeutics: Consultant (X Relationship Ended); Merck, Inc: Speaker (X Relationship Ended) |
| Layal | Chaker | Abbott: In kind research funding |
| Carrie  | Cunningham | 3M: Consultant |
| Terry  | Davies | Kronus Inc.: Board Member; Imunovant: Advisory Board; Horizon: CME Speaker (X Relationship Ended); Up To Date: Card Author |
| Leonidas | Duntas | Merck KGgA: Speaker (X Relationship Ended); Berlin Chemie: Speaker (X Relationship Ended) |
| Cosimo | Durante | Eisai: Invited speaker (X Relationship Ended); Lilly: Invited speaker (X Relationship Ended); IPSEN: Invited Speaker (X Relationship Ended) |
| Rossella | Elisei | Elsai: Consultant; Lilly: Consultant; Bayer: Consultant; Roche: Consultant (X Relationship Ended); Ipsen: Consultant (X Relationship Ended) |
| Giuseppe Barb | Esino | Horizon Therapeutics: Consultant; Immunovant: Consultant; Worg Pharma: Consultant (X Relationship Ended) |
| James | Fagin | Kura Oncology: Royalties |
| Mark  | Frye | Assurex Health: researcher; Breakthrough Discoveries for Thriving with Bipolar Disorder (BD2):consultant;Milken Institute :consultant ; Carnot Laboratories:CME speaker;American Physician Institute:CME speaker:Chymia LLC:Financial interest (X Relationship Ended) |
| Sana | Ghaznavi | Eisai: Consultant; Ipsen: Consultant (X Relationship Ended) |
| Benjamin | Gigilottie | Physicians Education Resouce, LLC: Faculty in Lecutuer in Oncolog Consultations Webinar: Adressing Clinical Gaps in Thyroid Cancer Maagment (X Relationship Ended) |
| Whitney | Goldner | Roche: Site PI of multicenter study [X Relationship Ended}; Siemens: Site PI of mulitcenter study |
| Elizabeth | Grubs | Eli Lilly: MD Anderson Cancer Center, the institution at which I work, receives funds to upport a thyroid cancer gistry which I usilize; Exelixis: MD Anderson Cancer Center, the institution at which I work, receives funds to support a thyroid cancer registry which I utilize  |
| Malini | Gupta | Abbvie; Creative Consultant; IBSA: Speaker; Horizon: Speaker Advisory Board; Novo Nordisk: Advisory Board (X Relationship Ended) |
| Julien  | Hadoux | Lilly: Consultant (X Relationship Ended); HRA pharma:Consultant (X Relationship Ended);Roche: Consultant; Pharma Mar: Consultant: (X Relationship Ended);AAA - Novartis: Speaker; EISAI: Speaker |
| Meredith | Hartley | Autobahn Therapeutics, Inc: Consultant, Royalties, Stock Options |
| Adrian  | Harvey | Qualisure Diagnostics: Advisory Board |
| Bryan  | Haugen | Elsai: Advisory Board (X Relationship Ended) |
| Alan | Ho | Exelixis: Advisory Board; Rgenta: Consultant; Eisai: Advisory Board; Remix Therapeutics: Advisory Board; Affyimmune: Data Safety Monitoring Board; Coherus: Advisory Board (x Relationship Ended); Kura Oncology:Advisory Board; Merck: Advisory Board (x Relationship Ended); Elevar Therapeutics: Advisory Board(x Relationship Ended); Ayala Therapeutics: Advisory Board ( x Relationship Ended) |
| Thanh D. | Hoang | Acella: Advisor, Consultant (No financial compensations); Horizons Therapeutics: Advisor (No financial compensation) |
| Ana O. | Hoff | Eli Lilly: Libretto-531 Steering Commiottee; Eli Lilly: Research Funding (Institution); Novartis: Research Funding (Institution); Knight: Advisory Board (X Relationship Ended); Bayer: Lecture, Advisory Board(X Relationship Ended) |
| Anthony | Hollenberg | Eli Lilly: Data safety monitoring board; Novo Nordisk: Data safety monitoring board; Glaxo Smith Kline: Data safety monitoring board; Astra Zeneca: Data safety monitoring board |
| Mimi | Hu | Eli Lilly & Co: Researcher, Steering committe member (no personal funds) |
| Timothy | Huber | Pulse Biosciences: Consultant; Teawong Medical: Honoraria |
| Sina | Jasim | Horizon: Advisory meeting on TED last year (X Relationship Ended) |
| Julie Hallanger | Johnson | HRA Pharma: Consultant |
| Jeffrey A. | Knauf | Kura Oncology: Royalties  |
| Tim | Korevaar | Berlin Chemie: Speaker (X Relatioship Ended); IBSA: Speaker (Relationship Ended); Merck: Speaker (X Relationship)  |
| Anupam | Kotwal | Horizon Therapeutics: Advisory Board |
| Jennifer H | Kuo | Medtronic:Consultant |
| Paul W. | Ladnson | Viking Therapeutics: Consultant; Veracyte: Consultant |
| Mark  | Lupo | Roche Diagnostics: Research Funds (X Relationship Ended); Abbvie: Speaker/Consultant; Eisal: Speaker/Consultant;Indterpace Diagnostics: Speaker/Consultant;Ortho-Quidel:Speaker/Consultant;Takeda:Research Funds |
| Cary N. | Maraiash | Horizon Therapeutics: Consultant (X Relationship Ended) |
| Nicole | Massoll | Interspace Bioscience: Consultant |
| Elizabeth | McAnich | Acella/Avion Pharmaceuticals: Consultant; Abbvie Inc: Consultant; Equillbrate Therapeutics LLC: Co-founder |
| Bryan | McIver | EISAI – Advisory Board; speakerLexo- Lilly – Advisory Board; speakerExelixis– Advisory Board; speaker |
| Mizuho | Mimoto | Pfizer, Inc: Spouse's Employer (salary/stock) |
| Paola  | Mina-Osorio | Immunovant,Inc.: Employee |
| Joanna | Miragaya | Horizon:Medical Advisor for Horizon (X Relationship)  |
| Jae Hoon | Moon | Throscope Inc.: Patent beneficiary, Executive role  |
| Marina  | Nikiforova | University of Pittspurgh: IP ownership and recive royalties related toThyroSeq.; Sonic Healthcare USA: Consultant |
| Julia | Noel | Pulse Biosciences: Consultant; RF Medical: Speaking Fee |
| Carmelo | Nucera | Affyimmune: Translational Advisor, Stocks |
| Lisa A. | Orloff | Ascendis Pharma: Clinicians Advisory Board 6/12-13/2023 (X Relationship Ended) |
| Ioannis | Papagiannis | Horizon Therapeutics: Consultant, Advisor, Speaker |
| Tejal | Patel | Endocrine Fellows Foundation: Research Funding; Dexcom Inc:Research Products/Funding |
| Jaemin | Park | Throscope Inc:ECO |
| Elizabeth N. | Pearce | Merck China: Honoraria for iodine lecutures (X Relationship Ended) |
| Raquel Amira Cano | Penaloza | Merck: Speaker; Abbott: Speaker; Valentech: Speaker (X Relationship Ended) |
| Mara | Roth | Exelixis: Site PI (X Reltationship Ended) |
| Sarimar Aguosto | Salgado | Exexllxis:Consultant-Advisory Board; Eli Lilly: Research & Speaker Bureau; Eisai: Consultant-Advisory Board (X Relationship Ended); Blueprint Medicine: Consultant: Advisory Board (X Relationship Ended) |
| Nadia  | Schoenmakers | Scientific Advisory Board (Travel Expenses) |
| Manisha H. | Shah | Eli-Lilly: Research funding to the institution for clinical trial (X Relationship Ended 6/28/2022; Merrick: Research funding to the institution for a clinical trial (X Relationship Ended 6/28/2022 |
| Maissie | Shindo | Mendaera: Consultantx1 (XRelationship Ended) |
| Russell | Smith | Mendaera: Adviser (XRelationship Ended) |
| Julie Ann | Sosa | Exellixis and Eli Lilly: Insitutional research funding through MD Anderson; Novo Nordisk, Astra Zeneca and Eli LIlly: Member, Data Monitoring Committee of the Medullary Thyroid Cancer Consortium Registry - Through UBC |
| Christine | Spitzweg | Lilly: Honoraria for lectures, advisory boards; Ipsen: honoraria for lectures, advisory boards; Eisai: Honoriaria for lectures, advisory boards; Sanofi Aventis: Hooriaria for lectures, advisory boards; Roche: Honoraria for lectures, advosory boards |
| Marius | Stan | Horizon Theraputics: Research support for my institutionll; Immunovant: Reascerch support for my institution; Valenzabio: Research support for my institution (X Relationship Ended); Sling Theraputics: Research support for my institution (X Relationship Ended); Lassen Theraputics: Research support for my institution; Tourmaline Inc.: Consultant; Genentech: Consultant; ArgenX: Consultant; Third Rock Ventures: Consultant;Septerna Inc./Ortho Clinical Diagnostics: Consultant; Roivant/OSE Immunotherapeutics: Consultant (X Relationship Ended/X Relationship Ended) |
| Vishnu  | Sundaresh | Radius Health, Inc.: Researcher (Research grant receipient 2019-2022) (X Relationship Ended) |
| Gerasimos | Sykiotis | Merck: Consulant, Speaker (X Relationship Ended); IBSA: Consultant, Speaker (X Relationship Ended); EISAI: Consultant (X Relationship Ended); Medtronic: Research funding |
| Silvania de Silva | Teixeira | Kronus Inc.: Board Member; Imunovant: Advisory Board; Horizon: CME Speaker; Up To Date: Card Author |
| Johnson | Thomas | Novo Nordisk: Speaker; AlBx: CEO |
| R. Michael | Tuttle | Elesta: My institution receives financial support for a pilot study of thermal ablation |
| Ralph | Tufano  | Pulse Bioscience: Consultant; Medtronic: Consultant; Stryker: Consultant; RGS Healthcare: Consultant |
| Tracy | Tylee | Abbvie: Consultant; Monad Biotech: Advisor |
| Erivelto  | Volpi | StarMed: Speaker (X Relationship Ended) |
| Kartik  | Viswanathan | Veracyte Inc. (Afirma): One time advisor (X Relationship Ended) |
| Steven | Wagnuespack | Bayer: Trave; reimbursement, speaker, consultant |
| Jonathan | Wasseman | Ispen Pharmaceuticals: Advisor (X Relationship Ended) |
| Ari | Wassner | UpToDate: Author/reviewer; Endocrine Society: Author (board review materials) |
| Stefano | Spiezia | Elesta Co: Conultant |
| Mark  | Zafereo | Merk: Grant; Eli Lilly: Grant |